Ritlecitinib for rheumatoid arthritis succeeds in phase II trial
Ritlecitinib, an oral JAK3/TEC inhibitor, appears to be well tolerated and produce significant improvements disease activity in patients with rheumatoid arthritis, according to the results of a phase II study.